We have delineated another downstream target of NF-κB, the cytokine/LPS-inducible form of nitric oxide synthase (iNOS), which may respond to NF-κB inhibitors as well and thereby modulate the radioresponse of tumour cells. Here, NOS2 is linked to neoplasm.